In vivo radioprotection by α-TMG

Preliminary studies

Merriline Satyamitra, P. Uma Devi, Hironobu Murase, V. Tsutomu Kagiya

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

α-TMG is a novel water-soluble derivative of Vitamin E that has shown excellent antioxidant activity. The parent compound has demonstrated protection against radiation induced chromosomal damage in vivo. Hence, the preliminary experiments to determine the radioprotective activity of α-TMG were carried out in adult Swiss albino mice. Acute toxicity of the drug was studied taking 24 h, 72 h and 30 day mortality after a single intraperitoneal injection of 500-2000 mg/kg body weight of the drug. The drug LD50 for 24 h and 72 h/30 day survival were found to be 1120 and 1000 mg/kg body weight, respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 600mg/kg of the drug 15min before or within 5, 15 or 30 min after 3 Gy whole body gamma radiation resulted in a significant decrease in the aberrant metaphases percent at 24 h post-irradiation; the maximum effect was seen when the drug was given immediately after irradiation. Injection of 200-800 mg/kg TMG within 5 min of irradiation with 3 Gy produced a significant dose-dependent reduction in the radiation induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 600 mg/kg body weight. At this dose, TMG produced 70 and >60% reduction in the radiation induced percent aberrant metaphases and micronucleated erythrocytes, respectively. The high water solubility and effectiveness when administered post-irradiation favor TMG as a likely candidate for protection in case of accidental exposures.

Original languageEnglish
Pages (from-to)53-61
Number of pages9
JournalMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Volume479
Issue number1-2
DOIs
Publication statusPublished - 08-08-2001
Externally publishedYes

Fingerprint

Metaphase
Pharmaceutical Preparations
Radiation Protection
Body Weight
Drug-Related Side Effects and Adverse Reactions
Erythrocytes
Radiation
Injections
Water
Whole-Body Irradiation
Lethal Dose 50
Gamma Rays
Intraperitoneal Injections
Vitamin E
Solubility
Antioxidants
Chromosomes
Bone Marrow
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

Satyamitra, Merriline ; Uma Devi, P. ; Murase, Hironobu ; Tsutomu Kagiya, V. / In vivo radioprotection by α-TMG : Preliminary studies. In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2001 ; Vol. 479, No. 1-2. pp. 53-61.
@article{ee32d73289074f879da0e1898864a05a,
title = "In vivo radioprotection by α-TMG: Preliminary studies",
abstract = "α-TMG is a novel water-soluble derivative of Vitamin E that has shown excellent antioxidant activity. The parent compound has demonstrated protection against radiation induced chromosomal damage in vivo. Hence, the preliminary experiments to determine the radioprotective activity of α-TMG were carried out in adult Swiss albino mice. Acute toxicity of the drug was studied taking 24 h, 72 h and 30 day mortality after a single intraperitoneal injection of 500-2000 mg/kg body weight of the drug. The drug LD50 for 24 h and 72 h/30 day survival were found to be 1120 and 1000 mg/kg body weight, respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 600mg/kg of the drug 15min before or within 5, 15 or 30 min after 3 Gy whole body gamma radiation resulted in a significant decrease in the aberrant metaphases percent at 24 h post-irradiation; the maximum effect was seen when the drug was given immediately after irradiation. Injection of 200-800 mg/kg TMG within 5 min of irradiation with 3 Gy produced a significant dose-dependent reduction in the radiation induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 600 mg/kg body weight. At this dose, TMG produced 70 and >60{\%} reduction in the radiation induced percent aberrant metaphases and micronucleated erythrocytes, respectively. The high water solubility and effectiveness when administered post-irradiation favor TMG as a likely candidate for protection in case of accidental exposures.",
author = "Merriline Satyamitra and {Uma Devi}, P. and Hironobu Murase and {Tsutomu Kagiya}, V.",
year = "2001",
month = "8",
day = "8",
doi = "10.1016/S0027-5107(01)00135-X",
language = "English",
volume = "479",
pages = "53--61",
journal = "Mutation Research",
issn = "1386-1964",
publisher = "Elsevier",
number = "1-2",

}

In vivo radioprotection by α-TMG : Preliminary studies. / Satyamitra, Merriline; Uma Devi, P.; Murase, Hironobu; Tsutomu Kagiya, V.

In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 479, No. 1-2, 08.08.2001, p. 53-61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo radioprotection by α-TMG

T2 - Preliminary studies

AU - Satyamitra, Merriline

AU - Uma Devi, P.

AU - Murase, Hironobu

AU - Tsutomu Kagiya, V.

PY - 2001/8/8

Y1 - 2001/8/8

N2 - α-TMG is a novel water-soluble derivative of Vitamin E that has shown excellent antioxidant activity. The parent compound has demonstrated protection against radiation induced chromosomal damage in vivo. Hence, the preliminary experiments to determine the radioprotective activity of α-TMG were carried out in adult Swiss albino mice. Acute toxicity of the drug was studied taking 24 h, 72 h and 30 day mortality after a single intraperitoneal injection of 500-2000 mg/kg body weight of the drug. The drug LD50 for 24 h and 72 h/30 day survival were found to be 1120 and 1000 mg/kg body weight, respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 600mg/kg of the drug 15min before or within 5, 15 or 30 min after 3 Gy whole body gamma radiation resulted in a significant decrease in the aberrant metaphases percent at 24 h post-irradiation; the maximum effect was seen when the drug was given immediately after irradiation. Injection of 200-800 mg/kg TMG within 5 min of irradiation with 3 Gy produced a significant dose-dependent reduction in the radiation induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 600 mg/kg body weight. At this dose, TMG produced 70 and >60% reduction in the radiation induced percent aberrant metaphases and micronucleated erythrocytes, respectively. The high water solubility and effectiveness when administered post-irradiation favor TMG as a likely candidate for protection in case of accidental exposures.

AB - α-TMG is a novel water-soluble derivative of Vitamin E that has shown excellent antioxidant activity. The parent compound has demonstrated protection against radiation induced chromosomal damage in vivo. Hence, the preliminary experiments to determine the radioprotective activity of α-TMG were carried out in adult Swiss albino mice. Acute toxicity of the drug was studied taking 24 h, 72 h and 30 day mortality after a single intraperitoneal injection of 500-2000 mg/kg body weight of the drug. The drug LD50 for 24 h and 72 h/30 day survival were found to be 1120 and 1000 mg/kg body weight, respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 600mg/kg of the drug 15min before or within 5, 15 or 30 min after 3 Gy whole body gamma radiation resulted in a significant decrease in the aberrant metaphases percent at 24 h post-irradiation; the maximum effect was seen when the drug was given immediately after irradiation. Injection of 200-800 mg/kg TMG within 5 min of irradiation with 3 Gy produced a significant dose-dependent reduction in the radiation induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 600 mg/kg body weight. At this dose, TMG produced 70 and >60% reduction in the radiation induced percent aberrant metaphases and micronucleated erythrocytes, respectively. The high water solubility and effectiveness when administered post-irradiation favor TMG as a likely candidate for protection in case of accidental exposures.

UR - http://www.scopus.com/inward/record.url?scp=0035828181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035828181&partnerID=8YFLogxK

U2 - 10.1016/S0027-5107(01)00135-X

DO - 10.1016/S0027-5107(01)00135-X

M3 - Article

VL - 479

SP - 53

EP - 61

JO - Mutation Research

JF - Mutation Research

SN - 1386-1964

IS - 1-2

ER -